<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dysregulated <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism and <z:mp ids='MP_0001845'>inflammation</z:mp> are linked to the development of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in <z:hpo ids='HP_0001513'>obesity</z:hpo>, and the intracellular accumulation of the <z:chebi fb="0" ids="26739">sphingolipid</z:chebi> <z:chebi fb="7" ids="17761">ceramide</z:chebi> has been implicated in these processes </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we explored the role of circulating <z:chebi fb="7" ids="17761">ceramide</z:chebi> on the pathogenesis of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="7" ids="17761">Ceramide</z:chebi> transported in <z:chebi fb="15" ids="39026">LDL</z:chebi> is elevated in the plasma of <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and correlated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> but not with the degree of <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Treating cultured myotubes with <z:chebi fb="15" ids="39026">LDL</z:chebi> containing <z:chebi fb="7" ids="17761">ceramide</z:chebi> promoted <z:chebi fb="7" ids="17761">ceramide</z:chebi> accrual in cells and was accompanied by reduced insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, Akt phosphorylation, and GLUT4 translocation compared with <z:chebi fb="15" ids="39026">LDL</z:chebi> deficient in <z:chebi fb="7" ids="17761">ceramide</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi>-<z:chebi fb="7" ids="17761">ceramide</z:chebi> induced a proinflammatory response in cultured macrophages via toll-like receptor-dependent and -independent mechanisms </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, infusing <z:chebi fb="15" ids="39026">LDL</z:chebi>-<z:chebi fb="7" ids="17761">ceramide</z:chebi> into lean mice reduced insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, and this was due to impaired insulin action specifically in skeletal muscle </plain></SENT>
<SENT sid="6" pm="."><plain>These newly identified roles of <z:chebi fb="15" ids="39026">LDL</z:chebi>-<z:chebi fb="7" ids="17761">ceramide</z:chebi> suggest that strategies aimed at reducing hepatic <z:chebi fb="7" ids="17761">ceramide</z:chebi> production or reducing <z:chebi fb="7" ids="17761">ceramide</z:chebi> packaging into <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> may improve skeletal muscle insulin action </plain></SENT>
</text></document>